Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Expanded_access × Melanoma × talimogene laherparepvec × Clear all

Status

No longer available 2

Sponsor Class

Study Type

Interventional 15 Expanded_access 2

Sponsor

Cancer Type

Conditions

Interventions

trametinib 3 dabrafenib 3 talimogene laherparepvec 2 pembrolizumab 2 Nivolumab 2 Ipilimumab 2 ulixertinib 1 tebentafusp 1 pegilodecakin 1 omaveloxolone 1 efineptakin alfa 1 balstilimab 1 aldesleukin 1 Melphalan 1 Cyclophosphamide 1 AM0010 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02297529 2019-10-31

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

Amgen

No longer available

Melanoma

NCT02147951 2016-03-01

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Amgen

No longer available

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡